Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
96 hedge funds and large institutions have $362M invested in Albireo Pharma Inc in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 31 reducing their positions, and 13 closing their positions.
124% more call options, than puts
Call options by funds: $1.99M | Put options by funds: $886K
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
2% more funds holding
Funds holding: 94 → 96 (+2)
10% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 31
24% less capital invested
Capital invested by funds: $477M → $362M (-$115M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$3.41M |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$1.87M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$1.84M |
| 4 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$1.81M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$8.19M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$2.39M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.65M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$1.37M |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$1.32M |
ALBO Hedge Fund Activity: Q4 2021 in Review
96 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q4 2021, worth a combined $362M — down 24% from $477M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new ALBO positions and 13 closed out — a net gain of 2 holders — while 34 added to existing stakes and 31 trimmed.
The largest buyer was MAI Capital Management, adding an estimated $3.41M. The largest seller was Baker Bros. Advisors, cutting an estimated $8.19M.
- 96 institutional investors held Albireo Pharma Inc (ALBO) as of Q4 2021, up from 94 in Q3 2021.
- Funds reported $362M of Albireo Pharma Inc stock for Q4 2021, down 24% quarter-over-quarter.
- 15 funds opened new Albireo Pharma Inc positions in Q4 2021 and 13 closed out, a net change of +2 holders.
- The largest Albireo Pharma Inc buyer in Q4 2021 was MAI Capital Management, an estimated $3.41M added.
- The largest Albireo Pharma Inc seller in Q4 2021 was Baker Bros. Advisors, an estimated $8.19M sold.
Based on aggregated 13F filings for Q4 2021.